secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001658247-26-000039
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics Q1 2026: PALSONIFY net revenue $10.3M; EU approval; net loss $127.8M
------------------------------------------------------------------------------

- PALSONIFY net product revenue $10.3M in Q1 2026, up from $5.4M in Q4 2025; 232 enrollment forms received.
- European Commission approved PALSONIFY for acromegaly in April 2026; MAA submitted to Brazil, NDA in Japan.
- Net loss $127.8M vs $96.8M in Q1 2025; cash $1.3B after $380M equity offering.
- Initiated BALANCE-CAH Phase 2/3 trial; on track to start Phase 2/3 trial for atumelnant in Cushing's in Q2 2026.
- 2026 GAAP operating expense guidance $600M-$650M; non-GAAP $480M-$520M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000165824726000039/0001658247-26-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000165824726000039/crnx-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001658247-26-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer